RxDoctor Payments Data

Anisha Bassi, MD

Internal Medicine · Glen Burnie, MDNPI 1154616878

Payments from drug & device makers

$12,649in general payments, 2019–2025

Across 757 payments — averaging $16.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Lilly USA, LLC$1K
  • AstraZeneca$961
  • AbbVie$942
  • Johnson & Johnson$683
  • Pfizer$663
  • plus $6K from 50 others

What the payments were for

  • Food & beverage$12,637100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,649 in reported general payments places this provider in the 90th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$180,793
Medicare patients
354
Services billed
1,674

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide82$115,501
EliquisApixaban82$108,695
JardianceEmpagliflozin69$94,644
MounjaroTirzepatide70$84,219
EntrestoSacubitril/Valsartan22$35,427
Trelegy ElliptaFluticasone/Umeclidin/Vilanter42$33,788
DescovyEmtricitabine/Tenofov Alafenam14$33,008
TrulicityDulaglutide23$32,171
XareltoRivaroxaban27$27,476
TivicayDolutegravir Sodium11$25,141
Bydureon BciseExenatide Microspheres18$24,244
LinzessLinaclotide18$22,551
FarxigaDapagliflozin Propanediol15$19,843
Tresiba Flextouch U-100Insulin Degludec16$14,095
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog27$13,404

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,141$116,39093 claims
Novo NordiskOzempic$1,821$115,50182 claims
PfizerEliquis$663$108,69582 claims
Boehringer IngelheimJardiance$433$94,64469 claims
NovartisEntresto$312$35,42722 claims
GSKTrelegy Ellipta$567$33,78842 claims
GileadDescovy$38$33,00814 claims
Johnson & JohnsonXarelto$683$27,47627 claims
AbbVieLinzess$942$22,55118 claims
AstraZenecaFarxiga$961$19,84315 claims
Sanofi-aventis U.S. LLCLantus$211$1,82312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Glen Burnie

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →